Association between TERT promoter mutations and clinical outcome with immune checkpoint inhibitor therapy for advanced urothelial cancer.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Neal Shiv Chawla, Nishita Tripathi, Nicolas Sayegh, Ameish Govindarajan, Nazli Dizman, Zeynep Busra Zengin, Luis A Meza, Ramya Muddasani, Alex Chehrazi-Raffle, Sabrina Salgia, Jasnoor Malhotra, Joann Hsu, Errol James Philip, Cristiane Decat Bergerot, Yung Lyou, Umang Swami, Sumati Gupta, Benjamin L. Maughan, Neeraj Agarwal, Sumanta K. Pal
Institutions: City Of Hope National Medical Center, Huntsman Cancer Institute, University of Utah Health Care, University of California, San Francisco, Universidade Federal de São Paulo, University of California, Irvine, University of Utah, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, City of Hope
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4213156495